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ABSTRACT
We have previously demonstrated a neuroprotective mech-
anism of FMN (facial motoneuron) survival after facial nerve
axotomy that is dependent on CD4
+ Th2 cell interaction with
peripheral antigen-presenting cells, as well as CNS (central
nervous system)-resident microglia. PACAP (pituitary adenyl-
ate cyclase-activating polypeptide) is expressed by injured
FMN and increases Th2-associated chemokine expression in
cultured murine microglia. Collectively, these results suggest
a model involving CD4
+ Th2 cell migration to the facial
motor nucleus after injury via microglial expression of
Th2-associated chemokines. However, to respond to Th2-
associated chemokines, Th2 cells must express the appropri-
ateTh2-associatedchemokinereceptors.Inthepresentstudy,
we tested the hypothesis that Th2-associated chemokine
receptors increase in the facial motor nucleus after facial
nerve axotomy at timepoints consistent with significant T-
cell infiltration. Microarray analysis of Th2-associated
chemokine receptors was followed up with real-time PCR
for CCR3, which indicated that facial nerve injury increases
CCR3 mRNA levels in mouse facial motor nucleus.
Unexpectedly, quantitative- and co-immunofluorescence
revealed increased CCR3 expression localizing to FMN in
the facial motor nucleus after facial nerve axotomy.
Compared with WT (wild-type), a significant decrease in
FMN survival 4 weeks after axotomy was observed in CCR3
2/2
mice. Additionally, compared with WT, a significant decrease in
FMN survival 4 weeks after axotomy was observed in Rag2
2/2
(recombination activating gene-2-deficient) mice adoptively
transferred CD4
+ T-cells isolated from CCR3
2/2 mice, but not
in CCR3
2/2 mice adoptively transferred CD4
+ T-cells derived
from WT mice. These results provide a basis for further
investigation into the co-operation between CD4
+ T-cell-
and CCR3-mediated neuroprotection after FMN injury.
Key words: CCR3, chemokine receptor, facial nerve axotomy,
neuroprotection.
INTRODUCTION
Our laboratory has previously demonstrated a positive role
for CD4
+ T-cells in FMN (facial motoneuron) survival after
peripheral facial nerve axotomy at the stylomastoid foramen
in the mouse (Serpe et al., 1999, 2003). Raivich et al. (1998)
have found a maximum increase in T-cell infiltration of the
axotomized mouse facial motor nucleus between 7 and 21
days after injury. Furthermore, Ha et al. (2007) demonstrated
a significant increase of CD4
+ T-cells in the facial motor
nucleus after facial nerve injury. In support of the findings by
Raivich et al. (1998) and Ha et al. (2007), our laboratory has
shown that CNS (central nervous system)-resident microglia
are necessary to reactivate CD4
+ T-cells centrally (Byram et
al., 2004), suggesting the mechanism of peripheral CD4
+ T-
cell recruitment to the injured facial motor nucleus from the
draining cervical lymph nodes.
Once activated, naı ¨ve CD4
+ T-cells differentiate into IL-4
(interleukin-4)-positive (IL-4
+) Th2 or IFNc (interferon c)-
positive (IFN-c
+) Th1 effector cells (Stout and Bottomly,
1To whom correspondence should be addressed (email Derekwainwright@hotmail.com).
2These authors share senior authorship.
Abbreviations: ALS, amyotrophic lateral sclerosis; CNS, central nervous system; DEPC, diethyl pyrocarbonate; DPA, days post-axotomy; FMN, facial motoneuron(s); GFAP,
glial fibrillary acidic protein; GPCR, G-protein-coupled receptor; PACAP, pituitary adenylate cyclase-activating polypeptide; PNS, peripheral nervous system; Rag2,
recombination activating gene-2; WT, wild-type.
E 2009 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://
creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is
properly cited.
RESEARCH ARTICLE
ASN NEURO 1(5):art:e00024.doi:10.1042/AN20090017
asnneuro.org / Volume 1 (5) / art:e00024 2991989). Previous work in our laboratory has found that both
Th2 and Th1 subsets develop in draining lymph nodes after
facial nerve axotomy (Xin et al., 2008), but that the Th2
effector subset alone is necessary for immune-mediated
neuroprotection (Deboy et al., 2006). Additionally, Armstrong
et al. (2003) demonstrated increased mRNA levels for PACAP
(pituitary adenylate cyclase-activating polypeptide) in FMN
after facial nerve axotomy. Since cultured murine microglia
exposed to PACAP increase Th2-associated chemokine
expression (Wainwright et al., 2008), the results suggest that,
following a peripheral nerve injury outside the BBB (blood–
brain barrier), microglia, which are capable of antigen
presentation centrally (Carson et al., 1999), recruit Th2 cells
to the facial motor nucleus. However, to respond to Th2-
associated chemokines, Th2 effector cells must express the
cognate Th2-associated chemokine receptors.
The recruitment of lymphocytes to different bodily
compartments is a highly regulated process that involves
chemokine receptors (Rand et al., 1996). Chemokine receptors
are GPCRs (G-protein-coupled receptors) that, upon activa-
tion, induce chemotaxis and calcium mobilization. Different
subsets of lymphocytes express different chemokine recep-
tors, reflecting their unique migration patterns. For example,
naı ¨ve CD4
+ T-cells that develop into the Th2 subset express
the Th2-associated chemokine receptor CCR3 (Sallusto et al.,
1997). Furthermore, while several Th2-associated chemokine
receptors have been demonstrated to be up-regulated by Th2
effector cells (Sallusto et al., 1998; Zingoni et al., 1998),
experiments with receptor antagonists have demonstrated a
critical requirement of CCR3 for Th2 cell accumulation after
antigenic challenge (Mori et al., 2007).
In summary, CD4
+ T-cells are present in the facial motor
nucleus after facial nerve injury (Ha et al., 2007), interact with
microglia (Byram et al., 2004) and protect FMN through a
Th2 cell-dependent mechanism (Deboy et al., 2006). Since Th2
cells are recruited by means of Th2-associated chemo-
kinereceptors, wehypothesizedthatTh2-associated chemokine
receptors increase in the facial motor nucleus after peripheral
facial nerve injury. To investigate this hypothesis, we initially
used microarray analysis to analyse Th2-associated chemokine
receptor mRNAlevelsinthe facialmotor nucleus at 7 DPA (days
post-axotomy), a time point consistent with significant T-cell
infiltration (Raivich et al., 1998). Based on microarray analysis,
we focused our investigation on the Th2-associated chemokine
receptor CCR3. In addition, co-immunofluorescence revealed
that CCR3 localizes to FMN and is increased after injury.
Furthermore,weusedthewell-establishedfacialnerveaxotomy
paradigm in conjunction with the CCR3-deficient (CCR3
2/2)
mouse model to show that CCR3 plays a role in rescuing FMN
survival after injury to the facial nerve. We followed this
analysis up with adoptive transfer mouse models including
CD4
+ T-cells derived from WT (wild-type) mice injected into
CCR3
2/2 mice, and CD4
+ T-cells isolated from CCR3
2/2 mice
injected into Rag2 (recombination activating gene-2)-deficient
(Rag2
2/2; immunodeficient) mice.
MATERIALS AND METHODS
Animals and surgical procedures
Seven-week old female C57BL/6 (stock # 000664) and Balb/c
(stock # 000651) mice were obtained from Jackson
Laboratories and Taconic respectively. Seven-week old mice
deficient for CCR3 (CCR3
2/2; Balb/c background) were a gift
from Dr Marc E. Rothenberg at Cincinnati Children’s Hospital
(Cincinnati, OH, U.S.A.). For adoptive transfer experiments,
7-week-old female CCR3
2/2 (stock # 005440) mice were
purchased from Jackson Laboratories and Rag2
2/2 (stock #
000601) mice were purchased from Taconic. All mice were
provided autoclaved food pellets and water ad libitum. Mice
were permitted 1 week to acclimatize to their environment
before being manipulated and used at 8 weeks of age in all
experiments. All experimental manipulations were performed
,4 h into the light cycle under aseptic conditions. All surgical
procedures were completed in accordance with NIH (National
Institutes of Health) guidelines on the care and use of
laboratory animals for research purposes. Mice were anaes-
thetized with 3% isoflurane for all surgical procedures. Using
aseptic techniques, the right facial nerve of each animal was
exposed and transected at its exit from the stylomastoid
foramen (Jones and LaVelle, 1985). The distal nerve stump was
pushed away from the proximal nerve stump, thereby
preventing reconnection of the facial nerve. Behavioural
observations were used to assess whether reconnection of the
facial nerve was prevented, i.e. did the animals recover from
unilateral facial paralysis. None of the animals in the present
study showed any signs of recovering from unilateral facial
paralysis after complete transection of the facial nerve.
Chemokine receptor gene array
At 7 DPA, C57BL/6 mice (n54) were killed with CO2 and the
brains rapidly removed. Coronal sections of brain stem,
including both facial motor nuclei, were collected and tissue
punches of the left (uninjured control) and right (axotomized)
facial motor nuclei obtained from these sections and pooled
(right axotomy compared with left control). The tissue punches
were placed into 0.65 ml microfuge tubes with 20 1.4 mm
Lysing Matrix D (Q-Biogene) and 80 mL of working solution D
(1 ml of solution D and 7.2 ml of 2-mercaptoethanol). RNA was
isolated from tissue punches and harvested cells by guanidi-
nium thiocyanate extraction (Chomczynski and Sacchi, 1987).
Samples were processed at the Superarray Bioscience Corpo-
ration using the Mouse Chemokines and Receptors Microarray
(OMM-022). Fold-changes in gene expression (right axotomy/
left control) were calculated for pair-wise comparison using
the GEArray Expression Analysis suite.
Laser microdissection
C57BL/6 mouse brains were removed at 7, 14 and 30 DPA
(n53–6/timepoint) and flash-frozen [in 62.5% n-butyl
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Scientific) surrounded by crushed dry ice]. Frozen brains
were sectioned on a Leica CM3000 cryostat (Leica) with a
temperature of 224˚C, immersed into Tissue Teck OCT
Compound (Sakura Finetek USA) at 25 mm intervals and
thaw-mounted on to membrane-coated glass slides (Leica
Microsystems). Slides were stained for Nissl substance to
visualize the facial motor nucleus and dehydrated sequen-
tially as follows: 100% ethanol (30 s), 26DEPC (diethyl
pyrocarbonate)-treated water (30 s each), working thionin
(30 s), 26DEPC-treated water (30 s each), 70% ethanol (30
s), 95% ethanol (30 s) and 100% ethanol (30 s). Slides were
dried in a closed container for 3 min. Laser microdissection of
left (control) and right (axotomized) facial motor nuclei using
the Leica AS LMD (Leica Microsystems) was accomplished,
capturing tissue into 0.5 ml microcentrifuge tube caps with
65 ml of extraction buffer (PicoPure RNA Isolation kit;
Arcturus). After microdissection for each animal, microfuge
tubes were spun at 800 g for 2 min to collect the cell extract
and were stored at 280˚C until use.
RNA isolation and real-time PCR
A PicoPure RNA Isolation kit (Arcturus) was used to extract
RNA following the manufacturer’s instructions. cDNA was
generated and used in real-time PCRs and amplification was
detected with SYBR green fluorescent dye (Applied
Biosystems). The following primers were obtained from
Superarray Bioscience Corporation: CCR3 (GenBankH accession
number NM 009914; PPM03173A-200) and GAPDH (glycer-
aldehyde-3-phosphate dehydrogenase; GenBankH accession
number NM 008084; PPM02946E-200). GAPDH served as the
reference gene. Amplification was performed using the iCycler
iQ Detection System (Bio-Rad Laboratories) under the
following conditions: 10 min at 95˚C, followed by 40 cycles
of 30 s at 95˚C, 30 s at 54˚C and 30 s at 65˚C. For each sample,
the percentage change in CCR3 mRNA levels was calculated
using the formula: [(axotomy/control)6100]2100%.
Preparation of CD4
+ T lymphocyte adoptive
transfers
Spleenswereaseptically removedfromBalb/c(WT) orCCR3
2/2
mice and placed in HBSS (Hanks balanced salt solution; Gibco
Invitrogen) and 5% FCS (fetal calf serum; Gibco Invitrogen).
Spleens were pressed through a 100 mm cell strainer (Fisher
Scientific) to remove splenic capsules. Whole splenocytes were
prepared as previously described (Serpe et al., 1999, 2003;
Byram et al., 2003; Deboy et al., 2006) to obtain a single cell
suspension. Briefly, red blood cells were lysed with 0.8%
ammonium chloride. Cells were washed in complete media
(cRPMI; Gibco Invitrogen) and centrifuged in Lympholyte M
(Cedarlane) at 1510 g for 20 min. The resulting cell interface
containinglymphocyteswascollectedand washedincRPMI.To
select for CD4
+ T-cells, lymphocytes were washed with running
buffer [PBS (Gibco Invitrogen), 0.5% BSA (Sigma–Aldrich) and
2 mM EDTA (Ambion)]. As previously described (Byram et al.,
2003; Serpe et al., 2003; Deboy et al., 2006), resuspension of
10
7 lymphocytes per 90 ml of running buffer and 10 mlo f
MACS (magnetic cell sorting) CD4 (L3T4) microbeads (Miltenyi
Biotec) were incubated for 15 min at 6–12˚C. Lymphocytes
were washed in running buffer by centrifugation at 300 g for
10 min, resuspended in 1–10 ml of running buffer and passed
through a 30 mM filter (Miltenyi Biotec) prior to magnetic cell
separation with an autoMACS automated cell sorter (Miltenyi
Biotec). CD4
+ T-cells were resuspended in PBS to 0.5610
7
cells/ml, and 0.2 ml of cell suspension or vehicle alone was
injected into the lateral tail vein of recipient mice 1 week prior
to axotomy. Adoptively transferred mouse groups included
CD4
+T-cellsderivedfromWTmiceinjectedintoCCR3
2/2mice,
and CD4
+ T-cells isolated from CCR3
2/2 mice injected into
Rag2
2/2 mice.
Cell-counting procedure for FMN survival
At 4 weeks after facial nerve axotomy, mouse brains were
removed and flash-frozen from WT (n55), CCR3
2/2 (n56),
CCR3
2/2 adoptively transferred CD4
+CCR3
+ T-cells (n56) and
Rag2
2/2 adoptively transferred CD4
+CCR3
2/2 T-cells (n56).
Cryostat sections (25 mm) were collected throughout the
rostral-caudal extent of the facial motor nucleus. Sections
were matched so that the rostral end of the control and
axotomized facial motor nucleus with the facial nerve from
each side were aligned (Serpe et al., 1999). Surviving FMNs
were counted based on the presence of a clear nucleolus.
Sections were coded by an investigator and cell counting was
performed by a different blinded investigator, where the
percentage change between the left and right sides was
calculated and compared between groups. The Abercrombie
correction factor {N5n6[T/(T+D)]}, where N is the actual
number of cells, n is the number of nuclear profiles, T is the
section thickness (25 mm) and D is the average diameter of
nuclei (5 mm) (Coggeshall, 1992), was used to compensate for
double counting in adjacent sections (Serpe et al., 1999).
Immunohistochemistry
At 14 DPA, C57BL/6 mice were killed with CO2 and the brains
flash frozen as previously described. Mouse brains were
sectioned at a thickness of 8 mm and thaw-mounted (37˚Cf o r
5–10 min)on to pre-cleaned SuperFrost slides(Fisher Scientific).
Sections were pre-incubated with 4% (w/v) paraformaldehyde,
blocked for endogenous biotin for 5 min (1% H2O2 in PBS),
and blocked for non-specific staining with 10% BSA (A4503,
Sigma–Aldrich) in PBS for 1 h. Sections were incubated
overnight with a rabbit anti-CCR3 antibody (AHP1010, AbD
Serotec) in PBS at 4˚C. Sections were washed extensively (in
PBS) and incubated with a biotinylated donkey anti-rabbit
antibody (Santa Cruz Biotechnology) at room temperature
(25˚C) for 1 h, followed by an avidin–biotin–HRP (horseradish
peroxidase) complex (Standard Ultra-Sensitive ABC Staining
Kit), and chromogenic reaction with 3,39-diaminobenzidine
CCR3-mediated neuroprotection after axotomy
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301(Peroxidase Substrate Kit; Vector Laboratories). Sections were
covered with Permount (Fisher Scientific), coverslipped and
viewed using an Olympus IX70 Fluoview microscope. As a
negativecontrol,adjacent sectionswere processedwith primary
antibody omission (secondary antibody only). Additionally,
preliminary experiments were performed with an anti-CCR3
antibody dilution series of 1:50, 1:100, 1:500, 1:1000 and
1:10000. While the 1:500 dilution resulted in the highest
signal-to-noise ratio, no signal was detected at 1:10000.
Co-immunofluorescence
At 14 DPA, C57BL/6 mouse brains were flash-frozen, sectioned,
and blocked for endogenous biotin and non-specificbinding as
described above. Primary rabbit anti-CCR3 antibody (AbD
Serotec) was incubated with biotinylated mouse anti-NeuN
antibody (A60, Millipore), mouse anti-GFAP (glial fibrillary
acidic protein)–Alexa FluorH 488 antibody (131-17719,
Invitrogen) or rat-anti-CD68-Alexa FluorH 488 antibody
(FA-11, AbD Serotec) and were incubated in PBS at 4˚C
overnight. Sections were washed and incubated with donkey
anti-rabbit–Alexa FluorH 350 antibody (Invitrogen) and
streptavidin–Alexa FluorH-488 antibody (for NeuN; Invitro-
gen), or donkey anti-rat-Alexa FluorH-488 (for CD68;
Invitrogen) for 1 h. Following extensive washing, sections
were covered with ProLong Gold Antifade reagent (Invitrogen)
and immediately visualized on an Olympus IX70 Fluoview
microscope.
Quantitative immunoreactivity
At 14 DPA, C57BL/6 mouse brains were flash-frozen, sectioned,
and blocked for endogenous biotin and non-specificbinding as
described above. Seven 14 DPA systematically random sampled
sections of brain stem, throughout the extent of the facial
motor nucleus, with a minimum of 80 mm between each
section, were analysed (n53). Sections were incubated
overnight with a rabbit anti-CCR3 antibody (AbD Serotec) in
PBS at 4˚C. Sections were washed extensively (in PBS) and
incubated with a biotinylated donkey anti-rabbit antibody
(Santa Cruz Biotechnology) at room temperature for 1 h,
washed and incubated with streptavidin-conjugated Alexa
FluorH-488 for 30 min. Following extensive washing, sections
were covered with ProLong Gold Antifade reagent (Invitrogen).
Additionally, directly adjacent sections were thionin-stained as
described above. Images of antibody-stained sections were
captured using the Olympus IX70 Fluoview fluorescent
microscope attached to a Retiga 2000R (QImaging) CCD
(charge-coupled-device) camera and image-capturing system
usingImage ProPlus software (version6.3; Media Cybernetics).
Fluorescent images of control and 14 DPA facial motor nucleus
were captured using a 106 objective and 1006 magnifica-
tion, with identical camera settings. CCR3
+ and thionin
+ FMN
were counted by an independent investigator blinded to the
experimental conditions. For each sample, the percentage of
CCR3
+ FMN was calculated using the formula [(CCR3
+ FMN/
thionin
+ FMN)6100]. Additionally, using the pixel histogram
generated for each original image, the product of the pixel
number and pixel intensity value (0–255) was computed and
summed for the entire facial motor nucleus. This provided a
composite measurement of changes in both the immunor-
eactive area and fluorescence intensity.
Statistical analysis
All results are presented as means¡S.E.M. The results from
the experiments were analysed using GB-STAT School Pak
(Dynamic Microsystems). FMN survival data were analysed
using ANOVA, followed by post-hoc comparisons using the
Fisher’s LSD (least significant difference) test. All other data
were analysed using ANOVA, followed by post-hoc compar-
isons using the Newman–Keuls test.
RESULTS
CCR3 mRNA levels increase in the facial motor
nucleus after axotomy
To determine whether Th2-associated chemokine receptor
mRNA levels are increased in the facial motor nucleus after
facial nerve injury, a preliminary microarray analysis was
performed. At 7 DPA, mRNA levels were increased for the
three examined Th2-associated chemokine receptors, CCR3,
CCR4 and CCR8 (87.2-, 11.3- and 9.6-fold respectively), in WT
mice (Figure 1). Thus facial nerve axotomy appears to
increase mRNA levels for Th2-associated chemokine receptors
in WT mouse facial motor nucleus.
Because CCR3 mRNA changes were so much greater, CCR3
mRNA expression was further analysed with real-time PCR
(Figure 2). At 7 DPA, WT mouse CCR3 mRNA levels were
1403¡199% above control values, significantly above 14 DPA
and 30 DPA values [459¡127% and 115¡126% respectively
(P,0.01)]. Thus facial nerve axotomy increases CCR3 mRNA
levels in mouse facial motor nucleus within the first week
after injury, before significantly decreasing over the next
several weeks.
CCR3 is involved in CD4
+ T-cell-mediated FMN
survival following axotomy
To determine whether the CCR3 receptor plays a role in FMN
survival after injury, a right facial nerve axotomy was
performed on WT and CCR3
2/2 mice. In WT mice, FMN
survival levels were 82¡3.0%, relative to control values at
4 weeks post-axotomy (Figures 3A and 3B). In contrast, in
CCR3
2/2 mice, FMN survival levels were significantly
decreased to 65¡4.0%, relative to control values (P,0.05),
a ,17% decrease when compared with WT. To determine
whether the CCR3 receptor on CD4
+ T-cells plays a role in
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CCR3
2/2 mice that were adoptively transferred CD4
+ T-cells
from WT mice. In CCR3
2/2 mice adoptively transferred WT T-
cells, FMN survival levels were slightly decreased to
75¡4.0%, relative to control values, and were not signifi-
cantly different compared with WT. To confirm whether the
CCR3 receptor on CD4
+ T-cells plays a role in FMN survival, a
right facial nerve axotomy was performed on Rag2
2/2 mice
that were adoptively transferred CD4
+ T cells from CCR3
2/2
Figure 1 Th2-associated chemokine receptor mRNA levels in mouse facial
motor nucleus 7 DPA
Chemokine receptor mRNA levels are displayed as the fold-change between
the axotomized side and the uninjured control side.
Figure 2 CCR3 mRNA levels in axotomized mouse facial motor nucleus 7,
14 and 30 DPA
CCR3 mRNA levels in the facial motor nucleus at 7, 14 and 30 DPA (values are
means¡ S.E.M.). CCR3 levels are displayed as the percentage change in facial
motor nuclei in the axotomized relative to control facial motor nucleus
within each animal. *P#0.01.
Figure 3 FMN survival levels 4 weeks after facial nerve axotomy in mice that are WT, CCR3
2/2, CCR3
2/2 adoptively transferred WT
mouse CD4
+ T-cells or Rag2
2/2 adoptively transferred CCR3
2/2 mouse CD4
+ T-cells
(A) Thionin-stained FMNs in control or axotomized facial motor nuclei of mice that are WT, CCR3
2/2, CCR3
2/2 adoptively
transferred WT mouse CD4
+ T-cells or Rag2
2/2 adoptively transferred CCR3
2/2 mouse CD4
+ T-cells (original magnification, 610).
(B) Average percentage of FMN survival after facial nerve injury (values are means¡S.E.M.). *P#0.05.
CCR3-mediated neuroprotection after axotomy
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303mice. In Rag2
2/2 mice adoptively transferred CCR3
2/2 T-
cells, FMN survival levels were significantly decreased to
65¡7.0%, relative to control values (P,0.05), a ,17%
decrease when compared with WT. Thus CCR3 expression by
CD4
+ T-cells appears to be required for maintaining FMN
survival levels after injury.
Constitutive expression of CCR3 on normal FMN
To determine CCR3 localization in the control (uninjured)
facial motor nucleus, CCR3 immunohistochemistry was
performed on uninjured brainstem sections (Figure 4). CCR3
was observed in FMN nuclei in the facial motor nucleus as
shown at low and high power. In control experiments in
which the primary antibody was omitted, CCR3 immuno-
reactivity was abolished. To verify that CCR3 localized to FMN
nuclei, co-immunofluorescence for CCR3 and NeuN (a
neuronal nuclei marker) was accomplished in the control
facial motor nucleus. Co-localization of CCR3 with NeuN
demonstrated labelling overlap and confirmed that CCR3
localizes to the nucleus of FMN in the uninjured facial motor
nucleus. Thus there is expression of CCR3 in normal FMN
nuclei.
To determine CCR3 localization in the injured facial motor
nucleus, CCR3 immunohistochemistry was performed on
brainstem sections from animals 14 DPA (Figure 5). CCR3
was observed in FMN cytoplasm throughout the facial motor
nucleus, as shown at low and high power. Additional
immunofluorescent experiments with a microglial marker,
CD68, and an astrocytic marker, GFAP, demonstrated no
overlap of signal. Thus injured FMN continue to express CCR3,
but there is de novo localization to the cytoplasm.
Additionally, there is no injury-induced expression of CCR3
on microglia or astrocytes.
CCR3 immunoreactivity increases in the facial
motor nucleus after axotomy
To quantify CCR3 immunoreactivity, CCR3 immunofluores-
cence was performed on brainstem sections from animals at
14 DPA (Figure 6A). The percentage of CCR3
+ FMN with
nucleus-only CCR3 immunoreactivity in control and 14 DPA
facial motor nuclei were 49¡0.6% and 16¡2.0% respect-
ively (Figure 6B). The percentage of CCR3
+ FMN with
cytoplasm-only CCR3 immunoreactivity in control and 14
DPA facial motor nuclei were 1.1¡1.1% and 37¡0.8%
respectively. The percentage of CCR3
+ FMN with both nuclei
and cytoplasm CCR3 immunoreactivity in control and 14 DPA
facial motor nuclei were 0% and 33¡3.6% respectively.
Therefore the percentage total of CCR3
+ FMN with nuclear
immunoreactivity in control and 14 DPA facial motor nuclei
was equivalent at 49%. In contrast, the percentage total of
Figure 4 CCR3 immunoreactivity in control mouse facial motor nucleus
(A) Low- (original magnification, 6100) and high- (original magnification, 6600) power photomicrographs of mouse facial motor
nucleus. Sections were processed for CCR3 immunohistochemistry. Control experiments include omission of CCR3 primary antibody.
(B) High-power immunofluorescence photomicrographs of mouse facial motor nucleus immunoreactive for anti-NeuN (green) and
anti-CCR3 (red) antibodies. Photomicrographs are based on the typical result of at least four independent experiments.
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+ FMN with cytoplasmic immunoreactivity in control
and 14 DPA facial motor nuclei were 1.1% and 70% respec-
tively. Collectively, the percentage total CCR3
+ FMN in
control and 14 DPA facial motor nuclei were 50¡1.6% and
86¡5.6% respectively (Figure 6C). Overall, the CCR3 mean
fluorescence intensities in the control and 14 DPA facial motor
nuclei were 0.7¡0.09 and 3.3¡0.18 (P,0.01) (Figure 6D).
This represented a significant increase of 371% of CCR3
expression in the facial motor nucleus after facial nerve
axotomy. Thus facial nerve axotomy increases the number of
CCR3-expressing FMN, the expression of CCR3 in the
cytoplasm of FMN, as well as total CCR3 immunoreactivity.
DISCUSSION
The present study was initiated based on previous work from
our laboratory demonstrating that mouse FMN survival after
facial nerve axotomy depends on both peripheral antigen-
presenting cells for initial CD4
+ T-cell activation, and
centrally located microglia for CD4
+ T-cell reactivation
(Byram et al., 2004). Furthermore, we discovered that, after
facial nerve axotomy, CD4
+ Th2 cells develop (Xin et al., 2008)
and are responsible for mediating FMN survival (Deboy et al.,
2006). These results, combined with evidence that PACAP
mRNA is expressed by injured mouse FMN after facial nerve
axotomy (Armstrong et al., 2003), and that PACAP increases
Th2-associated chemokine expression in cultured murine
microglia (Wainwright et al., 2008), strongly encouraged us to
undertake the present study. Using microarray analysis, we
initially identified an increase in Th2-associated chemokine
receptor CCR3 mRNA levels in the mouse facial motor nucleus
after facial nerve axotomy. Based on this preliminary analysis,
combined with previous data suggesting that Th2 cells
migrate to the facial motor nucleus after facial nerve
axotomy (Byram et al., 2004; Deboy et al., 2006), and that
Th2 cell-expressed CCR3 was required for efficient Th2 cell
migration (Mori et al., 2007), we chose to focus on the role
of CCR3 in the facial motor nucleus after facial nerve
axotomy.
Gao et al. (1996) first identified and characterized mouse
CCR3 with respect to the high level of mRNA expression in
eosinophils, as well as the calcium-mobilization response to
the Th2-associated chemokine, CCL11, in HEK (human
embryonic kidney)-293 cells. Since then, the majority of
research investigating CCR3 has focused on Th2 cell and
eosinophil recruitment to the lungs and resulting pathogen-
esis of asthma and allergies (Pope et al., 2005; Fulkerson et al.,
2006; Munitz et al., 2008). However, it is now clear that CCR3
is expressed by additional cell types.
Although it has previously been reported that CCR3
localizes to neurons in the CNS (Zhang et al., 1998), no
Figure 5 CCR3 immunoreactivity in 14 DPA mouse facial motor nucleus
(A) Low- (original magnification, 6100) and high- (original magnification, 6600) power photomicrographs of mouse facial motor
nucleus. Sections were processed for CCR3 immunohistochemistry. (B) High-power immunofluorescence photomicrographs of mouse
facial motor nucleus immunoreactive for anti-CD68 (green) and anti-CCR3 [red; left-hand panel)] or anti-GFAP (green) and anti-
CCR3 [red; right-hand panel)] antibodies. Photomicrographs are based on the typical result of at least four independent experiments.
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305other studies have demonstrated the effect of injury on
neuron-expressed CCR3. Previous reports have suggested that
the chemokine receptors CXCR2, CCR5 and CX3CR1 have the
potential to modulate neuronal survival after an injury
(Meucci et al., 2000; Cardona et al., 2006; Valle `s et al., 2006;
Gamo et al., 2008). Prior to this investigation, it was unknown
whether CCR3 was required to mediate neuronal survival
after an injury. It was also unknown whether CCR3 was
required by FMN, CD4
+ T-cells or both cell types, to mediate
FMN survival after facial nerve injury.
In the present study, the preliminary microarray analysis
led us to focus on the chemokine receptor CCR3. The results
indicate a transient, but large, increase in CCR3 mRNA levels
in WT mice coincident with peripheral immune activation.
Unexpectedly, normal FMN express CCR3 in the nucleus,
whereas axotomy-injured FMN express CCR3 in both the
nucleus and/or cytoplasm of FMN, and not in microglia or
astrocytes. Additionally, the percentage of CCR3
+ FMN and
quantitative immunofluorescence indicate a large increase in
the number of FMN that express CCR3, as well as an increase
in total CCR3 expression throughout the facial motor nucleus
respectively.
Our results show that CCR3 is critical to maintaining WT
levels of FMN survival, since a facial nerve axotomy in CCR3
2/2
mice showed decreased FMN survival. Furthermore, our results
indicate that CCR3 expression by CD4
+ T-cells is required to
rescue FMN survival from axotomy-induced FMN loss, since
only WT, but not CD4
+ T-cells deficient for CCR3, could rescue
FMN survival after a facial nerve axotomy. Noticeably, FMN
survival levels after axotomy in CCR3
2/2 mice adoptively
transferred with WT CD4
+ T-cells are not statistically different
from CCR3
2/2 mice with no adoptive transfer. We hypothesize
that this may be due to the already fully populated CD4
+ T-cell
compartment in CCR3
2/2 mice, resulting in an inefficient
engraftment of the WT CD4
+ T-cell population that is
adoptively transferred. Regardless of the requirement of CCR3
by CD4
+ T-cells to mediate FMN survival after axotomy, the
question still remains as to the role of CCR3 expressed by FMN.
Figure 6 Quantitative immunoreactivity for CCR3 in control and 14 DPA mouse facial motor nucleus
(A) Low- (original magnification, 6100) and high- (original magnification, 6600) photomicrographs of control (left-hand panels)
and axotomized (right-hand panels) mouse facial motor nucleus. (B) Average percentage of CCR3
+ FMN with nucleus only, cytoplasm
only or both nucleus and cytoplasm immunoreactivity in the control (open bars) and axotomized (grey bars) mouse facial motor
nucleus (values are means¡S.E.M.). (C) Average percentage total of CCR3
+ FMN in the control (open bars) and axotomized (grey
bars) mouse facial motor nucleus (values are means¡S.E.M.). (D) Mean fluorescence intensity of the control (open bars) and
axotomized (grey bars) mouse facial motor nucleus (values are means¡S.E.M.). *P#0.01. Con, control; Axo, axotomized.
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FMN was unexpected. However, immunohistochemistry for
CCR3 has previously demonstrated nuclear localization in
neurons (Zhang et al., 1998), as well as cells of the nasal
mucosa (Salib et al., 2004) and renal cell carcinoma (Jo ¨hrer
et al., 2005). Furthermore, numerous GPCRs have been
localized to the nucleus of cells in diverse tissues and have
been extensively reviewed (Goetzl, 2007; Boivin et al., 2008).
Although the significance of nuclear CCR3 localization has not
yet been investigated, the nuclear compartmentalization may
be the result of a transcription-factor-like function, involved
with maintenance and growth under normal conditions.
Possibly, CCR3 undergoes post-translational modifications
that target it toward the nucleus normally. Alternatively,
CCR3 may be trafficked to the nucleus from the plasma
membrane as a result of chemokine interaction. Recently,
CCR2 was shown to translocate from the cytoplasm to the
nucleus after activation by the cognate chemokine, CCL2, in
cultured HeLa cells (Favre et al., 2008). It is also possible that
CCR3 is alternatively spliced in FMN relative to peripherally
circulating leucocytes. Although not yet shown for chemokine
receptors, it has been demonstrated that some chemokines are
alternatively spliced in the CNS relative to the PNS (peripheral
nervous system), giving rise to a nuclear relative to a secreted
isoform respectively (Baird et al., 1999). Regardless of the
mechanism by which CCR3 is transported to the nucleus, clues
to the functional significance may be found in injured FMN.
After facial nerve axotomy, the percentage of FMN with
nuclear CCR3 immunoreactivity was maintained at constant
levels. In contrast, the percentage of FMN with cytoplasmic
immunoreactivity increased significantly. This translated into
a large increase in the percentage of total FMNs immunor-
eactive for CCR3. Accordingly, total CCR3 immunoreactivity
was increased in the facial motor nucleus after facial nerve
axotomy. Thus one of the effects of facial nerve axotomy in
FMN could be de novo synthesis of CCR3. Whether new CCR3
is inserted into the plasma membrane, translocated to the
nucleus and/or transported down FMN axons is an interesting
question. In accordance with our findings of changes in CCR3
expression in axotomized FMN, other immunohistochemical
experiments with the leukaemia inhibitor factor receptor
have demonstrated axotomy-induced changes in the intra-
cellular localization of immunoreactivity in DRG (dorsal root
ganglia) neurons (Gardiner et al., 2002). However, the
significance of the translocation was not determined.
The unexpected normal and/or injury-induced anatomical
location of CCR3 expression by FMN may be due, in part, to
the normal and/or injury-induced anatomical location of
chemokines that interact with CCR3. CCL5, CCL7, CCL8,
CCL11, CCL13, CCL15, CCL18, CCL24, CCL26 and CCL27 can all
bind CCR3 with variable affinities (Ponath et al., 1996; Coulin
et al., 1997; Heath et al., 1997; Stellato et al., 1997; White
et al., 1997; Shinkai et al., 1999; Nibbs et al., 2000; Pan et al.,
2000). Of those chemokines, only CCL11, CCL24 and CCL26
are reported to be specific to CCR3. The remaining
chemokines, CCL5, CCL7, CCL8, CCL13, CCL15, CCL18 and
CCL27, can interact with CCR3, in addition to other select
chemokine receptors. Given the plethora of chemokines that
interact with CCR3, as well as those that interact with
additional chemokine receptors, determining which CCR3-
interacting chemokines are required for FMN survival after
facial nerve injury provides a challenging opportunity.
In summary, in the present study it was determined that,
after facial nerve axotomy, CCR3 mRNA and protein levels
increase in the facial motor nucleus, CCR3 localizes to FMNs
and cytoplasmic immunoreactivity is elevated. Also, the
present study demonstrates, for the first time, a neuropro-
tective role for the chemokine receptor CCR3. It was
determined that CD4
+ T-cells require CCR3 to maintain WT
levels of FMN survival after a facial nerve injury. Co-
incidentally, it was previously demonstrated that CCR3 is
expressed by CD4
+ Th2 cells (Sallusto et al., 1997) and that
CD4
+ Th2 cells mediate WT levels of FMN survival after a
facial nerve injury through interaction with PNS antigen-
presenting cells, as well as CNS microglia (Byram et al., 2004;
Deboy et al., 2006). Taken together, these results indicate that
CCR3 is involved in the recruitment of CD4
+ Th2 cells to the
facial motor nucleus after facial nerve axotomy.
To maintain a healthy CNS, the immune system must
balance the destructive effects that develop for defence
against infection, disease or malignancy, with the neuropro-
tective effects that develop after a peripheral nerve injury
(Byram et al., 2004). In mouse models that recapitulate
motoneuron diseases such as ALS (amyotrophic lateral
sclerosis), data indicate that this balance is disturbed, resulting
in impaired chemokine receptor signalling (Luo et al., 2007).
Whether CCR3-expressing CD4
+ T-cells prevent disease onset
and/or slows disease progression during ALS pathogenesis is an
interesting hypothesis. Therefore future studies will investigate
the combined role of CCR3 and CD4
+ T-cells in mice that
recapitulate ALS pathology, as well as delineate the function of
CCR3 expression by FMN after injury.
ACKNOWLEDGEMENTS
We thank Dr Marc E. Rothenberg (Cincinatti Children’s Hospital,
Cincinnati, OH, U.S.A.) and Regeneron Pharmaceuticals
(Tarrytown, NY, U.S.A.) for CCR3-deficient mice.
FUNDING
This work was supported by the National Institutes of Health
[grant number NS40433 (to K.J.J. and V.M.S.)]; and the Les
Turner ALS Foundation (to D.A.W. and K.J.J.).
REFERENCES
Armstrong BD, Hu Z, Abad C, Yamamoto M, Rodriguez WI, Cheng J, Tam J,
Gomariz RP, Patterson PH, Waschek JA (2003) Lymphocyte regulation of
neuropeptide gene expression after neuronal injury. J Neurosci Res
74:240–247.
CCR3-mediated neuroprotection after axotomy
E 2009 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commerical use, distribution and reproduction in any medium, provided the original work is properly cited.
307Baird JW, Nibbs RJ, Komai-Koma M, Connolly JA, Ottersbach K, Clark-Lewis I,
Liew FY, Graham GJ (1999) ESkine, a novel b-chemokine, is differentially
spliced to produce secretable and nuclear targeted isoforms. J Biol Chem
274:33496–33503.
Boivin B, Vaniotis G, Allen BG, Hebert TE (2008) G protein-coupled receptors
in and on the cell nucleus: a new signaling paradigm? J Recept Signal
Transduct Res 28:15–28.
Byram SC, Serpe CJ, Pruett SB, Sanders VM, Jones KJ (2003) Natural killer
cells do not mediate facial motoneuron survival after facial nerve
transection. Brain Behav Immun 17:417–425.
Byram SC, Carson MJ, DeBoy CA, Serpe CJ, Sanders VM, Jones KJ (2004) CD4-
positive T cell-mediated neuroprotection requires dual compartment
antigen presentation. J Neurosci 24:4333–4339.
Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang
D, Kidd G, Dombrowski S, Dutta R, Lee JC, Cook DN, Jung S, Lira SA,
Littman DR, Ransohoff RM (2006) Control of microglial neurotoxicity by
the fractalkine receptor. Nat Neurosci 9:917–924.
Carson MJ, Sutcliffe JG, Campbell IL (1999) Microglia stimulate naı ¨ve T-cell
differentiation without stimulating T-cell proliferation. J Neurosci Res
55:127–134.
Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid
guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem
162:156–159.
Coggeshall RE (1992) A consideration of neuronal counting methods. Trends
Neurosci 15:9–12.
Coulin F, Power CA, Alouani S, Peitsch MC, Schroeder JM, Moshizuki M, Clark-
Lewis I, Wells TN (1997) Characterisation of macrophage inflammatory
protein-5/human CC cytokine-2, a member of the macrophage-
inflammatory-protein family of chemokines. Eur J Biochem 248:507–515.
Deboy CA, Xin J, Byram SC, Serpe CJ, Sanders VM, Jones KJ (2006) Immune-
mediated neuroprotection of axotomized mouse facial motoneurons is
dependent on the IL-4/STAT6 signaling pathway in CD4
+ T cells. Exp
Neurol 201:212–224.
Favre N, Camps M, Arod C, Chabert C, Rommel C, Pasquali C. (2008)
Chemokine receptor CCR2 undergoes transportin1-dependent nuclear
translocation. Proteomics 8:4560–4576.
Fulkerson PC, Fischetti CA, McBride ML, Hassman LM, Hogan SP, Rothenberg
ME (2006) A central regulatory role for eosinophils and the eotaxin/CCR3
axis in chronic experimental allergic airway inflammation. Proc Natl Acad
Sci USA 103:16418–16423.
Gamo K, Kiryu-Seo S, Konishi H, Aoki S, Matsushima K, Wada K, Kiyama H
(2008) G-protein-coupled receptor screen reveals a role for chemokine
receptor CCR5 in suppressing microglial neurotoxicity. J Neurosci
28:11980–11988.
Gao JL, Sen AI, Kitaura M, Yoshie O, Rothenberg ME, Murphy PM, Luster AD
(1996) Identification of a mouse eosinophil receptor for the CC
chemokine eotaxin. Biochem Biophys Res Commun 223:679–684.
Gardiner NJ, Cafferty WB, Slack SE, Thompson SW (2002) Expression of gp130
and leukaemia inhibitory factor receptor subunits in adult rat sensory
neurones: regulation by nerve injury. J Neurochem 83:100–109.
Goetzl EJ (2007) Diverse pathways for nuclear signaling by G protein-coupled
receptors and their ligands. FASEB J 21:638–642.
Ha GK, Huang Z, Parikh R, Pastrana M, Petitto JM (2007) Immunodeficiency
impairs re-injury induced reversal of neuronal atrophy: relation to T cell
subsets and microglia. Exp Neurol 208:92–99.
Heath H, Qin S, Rao P, Wu L, LaRosa G, Kassam N, Ponath PD, Mackay CR
(1997) Chemokine receptor usage by human eosinophils. The importance
of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin
Invest 99:178–184.
Jo ¨hrer K, Zelle-Rieser C, Perathoner A, Moser P, Hager M, Ramoner R, Gander
H, Ho ¨ltl L, Bartsch G, Greil R, Thurnher M (2005) Up-regulation of
functional chemokine receptor CCR3 in human renal cell carcinoma. Clin
Cancer Res 11:2459–2465.
Jones KJ, LaVelle A (1985) Changes in nuclear envelope invaginations in
axotomized immature and mature hamster facial motoneurons. Brain Res
353:241–249.
Luo Y, Xue H, Pardo AC, Mattson MP, Rao MS, Maragakis NJ (2007) Impaired
SDF1/CXCR4 signaling in glial progenitors derived from SOD1(G93A)
mice. J Neurosci Res 85:2422–2432.
Meucci O, Fatatis A, Simen AA, Miller RJ (2000) Expression of CX3CR1
chemokine receptors on neurons and their role in neuronal survival. Proc
Natl Acad Sci USA 97:8075–8080.
Mori A, Ogawa K, Someya K, Kunori Y, Nagakubo D, Yoshie O, Kitamura F,
Hiroi T, Kaminuma O (2007) Selective suppression of Th2-mediated
airway eosinophil infiltration by low-molecular weight CCR3 antagonists.
Int Immunol 19:913–921.
Munitz A, Brandt EB, Mingler M, Finkelman FD, Rothenberg ME (2008)
Distinct roles for IL-13 and IL-4 via IL-13 receptor a1 and the type II IL-4
receptor in asthma pathogenesis. Proc Natl Acad Sci USA 105:7240–
7245.
Nibbs RJ, Salcedo TW, Campbell JD, Yao XT, Li Y, Nardelli B, Olsen HS, Morris
TS, Proudfoot AE, Patel VP, Graham GJ (2000) C-C chemokine receptor 3
antagonism by the beta-chemokine macrophage inflammatory protein 4,
a property strongly enhanced by an amino-terminal alanine-methionine
swap. J Immunol 164:1488–1497.
Pan J, Kunkel EJ, Gosslar U, Lazarus N, Langdon P, Broadwell K, Vierra MA,
Genovese MC, Butcher EC, Soler D (2000) A novel chemokine ligand for
CCR10 and CCR3 expressed by epithelial cells in mucosal tissues.
J Immunol 165:2943–2949.
Ponath PD, Qin S, Ringler DJ, Clark-Lewis I, Wang J, Kassam N, Smith H,
Shi X, Gonzalo JA, Newman W, Gutierrez-Ramos JC, Mackay CR
(1996) Cloning of the human eosinophil chemoattractant, eotaxin.
Expression, receptor binding, and functional properties suggest a
mechanism for the selective recruitment of eosinophils. J Clin Invest
97:604–612.
Pope SM, Zimmermann N, Stringer KF, Karow ML, Rothenberg ME (2005) The
eotaxin chemokines and CCR3 are fundamental regulators of allergen-
induced pulmonary eosinophilia. J Immunol 175:5341–5350.
Raivich G, Jones LL, Kloss CU, Werner A, Neumann H, Kreutzberg GW (1998)
Immune surveillance in the injured nervous system: T-lymphocytes
invade the axotomized mouse facial motor nucleus and aggregate around
sites of neuronal degeneration. J Neurosci 18:5804–5816.
Rand ML, Warren JS, Mansour MK, Newman W, Ringler DJ (1996) Inhibition
of T cell recruitment and cutaneous delayed-type hypersensitivity-
induced inflammation with antibodies to monocyte chemoattractant
protein-1. Am J Pathol 148:855–864.
Salib RJ, Kumar S, Wilson SJ, Howarth PH (2004) Nasal mucosal
immunoexpression of the mast cell chemoattractants TGF-b, eotaxin,
and stem cell factor and their receptors in allergic rhinitis. J. Allergy Clin
Immunol 114:799–806.
Sallusto F, Mackay CR, Lanzavecchia A (1997) Selective expression of the
eotaxin receptor CCR3 by human T helper 2 cells. Science 277:2005–2007.
Sallusto F, Lenig D, Mackay CR, Lanzavecchia A (1998) Flexible programs of
chemokine receptor expression on human polarized T helper 1 and 2
lymphocytes. J Exp Med 187:875–883.
Serpe CJ, Kohm AP, Huppenbauer CB, Sanders VM, Jones KJ (1999)
Exacerbation of facial motoneuron loss after facial nerve transection in
severe combined immunodeficient (scid) mice. J Neurosci 19:RC7.
Serpe CJ, Coers S, Sanders VM, Jones KJ (2003) CD4
+ T, but not CD8
+ or B,
lymphocytes mediate facial motoneuron survival after facial nerve
transection. Brain Behav Immun 17:393–402.
Shinkai A, Yoshisue H, Koike M, Shoji E, Nakagawa S, Saito A, Takeda T,
Imabeppu S, Kato Y, Hanai N, Anazawa H, Kuga T, Nishi T (1999) A novel
human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated
vascular endothelial cells, exhibits potent activity toward eosinophils.
J Immunol 163:1602–1610.
Stellato C, Collins P, Ponath PD, Soler D, Newman W, La Rosa G, Li H, White J,
Schwiebert LM, Bickel C, Liu M, Bochner BS, Williams T, Schleimer RP
(1997) Production of the novel C-C chemokine MCP-4 by airway cells and
comparison of its biological activity to other C-C chemokines. J Clin
Invest 99:926–936.
Stout RD, Bottomly K (1989) Antigen-specific activation of effector
macrophages by IFN-c producing (TH1) T cell clones. Failure of IL-4-
producing (TH2) T cell clones to activate effector function in
macrophages. J Immunol 142:760–765.
Valle `s A, Grijpink-Ongering L, de Bree FM, Tuinstra T, Ronken E (2006)
Differential regulation of the CXCR2 chemokine network in rat brain
trauma: implications for neuroimmune interactions and neuronal
survival. Neurobiol Dis 22:312–322.
Wainwright DA, Xin J, Sanders VM, Jones KJ (2008) Differential actions of
pituitary adenylyl cyclase-activating polypeptide and interferon c on
Th2- and Th1-associated chemokine expression in cultured murine
microglia. J Neurodegen Regen 1:31–34.
White JR, Imburgia C, Dul E, Appelbaum E, O’Donnell K, O’Shannessy DJ,
Brawner M, Fornwald J, Adamou J, Elshourbagy NA, Kaiser K, Foley JJ,
Schmidt DB, Johanson K, Macphee C, Moores K, McNulty D, Scott GF,
Schleimer RP, Sarau HM (1997) Cloning and functional characterization
of a novel human CC chemokine that binds to the CCR3 receptor and
activates human eosinophils. J Leukoc Biol 62:667–675.
Xin J, Wainwright DA, Serpe CJ, Sanders VM, Jones KJ (2008) Phenotype of
CD4
+ T cell subsets that develop following mouse facial nerve axotomy.
Brain Behav Immun 22:528–537.
DA Wainwright and others
308 E 2009 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commerical use, distribution and reproduction in any medium, provided the original work is properly cited.Zhang L, He T, Talal A, Wang G, Frankel SS, Ho DD (1998) In vivo dis-
tribution of the human immunodeficiency virus/simian immuno-
deficiency virus coreceptors: CXCR4, CCR3, and CCR5. J Virol 72:
5035–5045.
Zingoni A, Soto H, Hedrick JA, Stoppacciaro A, Storlazzi CT, Sinigaglia F,
D’Ambrosio D, O’Garra A, Robinson D, Rocchi M, Santoni A, Zlotnik A,
Napolitano M (1998) The chemokine receptor CCR8 is preferentially
expressed in Th2 but not Th1 cells. J Immunol 161:547–551.
Received 3 April 2009/7 October 2009; accepted 12 October 2009
Published as Immediate Publication 19 November 2009, doi 10.1042/AN20090017
CCR3-mediated neuroprotection after axotomy
E 2009 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commerical use, distribution and reproduction in any medium, provided the original work is properly cited.
309